NAD+ injections and NAD+ IV therapy should not be used as treatments for high blood pressure. Some research involving oral NAD+ precursors—particularly nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR)—has reported small or preliminary blood-pressure effects in selected populations. Those findings do not establish that injectable or intravenous NAD+ lowers blood pressure, and they do not show that NAD+ can replace prescribed hypertension medication. That distinction is especially important if you already take medication for:
- high blood pressure;
- heart rhythm problems;
- heart failure;
- kidney disease;
- diabetes;
- or another cardiovascular or metabolic condition.
If you are considering NAD+ in any form, a clinician who knows your medical history and medication list should help assess whether it is appropriate. At Drip Lounge, NAD-related services should be considered within that clinical context—not as a substitute for established hypertension care.
Written by: Drip Lounge Editorial Team
Medically reviewed by: Megan Nickerson, DNP
Last medically reviewed: September 4, 2026
Evidence and safety review: September 4, 2026
Medical note: NAD+ injections, NAD+ IV therapy, and NAD-related supplements should not be used to treat high blood pressure or replace prescribed blood-pressure medication. Do not stop, skip, reduce, double, or change a blood-pressure medicine without guidance from the clinician who prescribes it.
Regulatory note: Injectable NAD+ products are not FDA-approved treatments for hypertension, heart disease, fatigue, anti-aging, recovery, or general wellness. Compounded drugs are also not FDA-approved products.
NAD+ and Blood Pressure at a Glance
| Question | Evidence-Based Answer |
|---|---|
| Does NAD+ lower blood pressure? | Not established for injectable or IV NAD+ |
| Has oral NMN been studied? | Yes, with mixed and generally modest findings |
| Has oral NR been studied? | Yes, including small cardiovascular studies |
| Do NMN/NR studies prove NAD+ injections work? | No |
| Is NAD+ an approved hypertension treatment? | No |
| Can NAD+ replace blood-pressure medication? | No |
| Is NAD+ automatically safe with antihypertensive medication? | That cannot be assumed |
| Should medication be changed because of an NAD+ treatment? | Not without prescribing-clinician guidance |
| Can blood pressure change during an IV visit? | Yes, for many possible reasons |
| Should a significant blood-pressure change be assessed? | Yes |
The most important concept throughout this article is:
Oral NAD+ precursor research ≠ NAD+ injection evidence ≠ NAD+ IV evidence ≠ approved hypertension treatment.
The Short Answer: Can NAD+ Lower Blood Pressure?
There is not enough evidence to consider NAD+ injections or NAD+ IV therapy treatments for high blood pressure. Some research involving oral NAD+ precursors has found small average blood-pressure changes. A 2023 meta-analysis of 29 studies involving 8,664 participants reported average reductions of approximately 2.54 mmHg in systolic blood pressure and 2.15 mmHg in diastolic blood pressure across NAD+ precursor interventions. But those interventions included precursor compounds rather than intravenous or injected NAD+ itself. More recent evidence has been more cautious. A 2026 meta-analysis specifically examining oral NMN included 349 participants from 10 randomized controlled trials. It found a small average reduction in diastolic blood pressure of about 2.15 mmHg, while the overall systolic change was not statistically significant. The authors described the findings as preliminary and called for larger, longer-term trials. These findings do not establish that:
- NAD+ injections lower blood pressure;
- NAD+ IV therapy lowers blood pressure;
- NAD+ is a hypertension medication;
- NAD+ is safe with every blood-pressure medication;
- or NAD+ can replace prescribed antihypertensive therapy.
NAD+, NAD Injections, NAD IV, NMN and NR Are Not the Same Thing
Online discussions frequently use “NAD” as though every NAD-related intervention is interchangeable. They are not.
| Term | What It Is | Common Route in Research or Practice | What You Should Not Assume |
|---|---|---|---|
| NAD+ | Nicotinamide adenine dinucleotide, a naturally occurring coenzyme | Naturally present in cells; also marketed intravenously or by injection | That its biological importance proves therapeutic benefit |
| NAD+ injection | Injectable NAD+ preparation | Injection | That oral NMN or NR evidence applies directly |
| NAD+ IV therapy | NAD+ administered intravenously | IV infusion | That it treats hypertension |
| NMN | Nicotinamide mononucleotide, an NAD+ precursor | Primarily oral in human research | That NMN studies establish effects from injected NAD+ |
| NR | Nicotinamide riboside, an NAD+ precursor | Primarily oral | That NR results prove NAD+ IV effectiveness |
| Nicotinic acid / niacin | A vitamin B3 form with its own pharmacology | Oral | That its effects can be generalized to NAD+ injections |
Why This Matters
NAD+ is central to many normal cellular processes. That does not mean delivering NAD+ intravenously produces the same clinical effects as taking an oral precursor. Different interventions can differ in:
- formulation;
- absorption;
- metabolism;
- route;
- exposure;
- safety;
- clinical oversight;
- study population;
- and evidence quality.
A 2026 systematic review of NAD-related interventions found that oral NR and NMN reliably affected NAD-related biomarkers, but human effects on vascular, metabolic, and other health outcomes remained mixed. Importantly, the review found no eligible clinical outcomes trials evaluating intravenous or intramuscular NAD+ itself for anti-aging or wellness indications. That evidence gap matters when interpreting blood-pressure claims too.
What Has Research Actually Found?
Nicotinamide Riboside and Blood Pressure
A widely cited 2018 randomized, double-blind, placebo-controlled crossover study examined oral nicotinamide riboside, not NAD+ injections. The study involved healthy middle-aged and older adults and found that NR increased NAD-related metabolism. Exploratory findings suggested that further research should investigate possible effects on blood pressure and arterial stiffness. That was an early signal—not proof that NR treats hypertension. It also cannot be translated into: “NAD+ IV lowers blood pressure.” The intervention was different.
What About NMN?
NMN has also attracted attention. The 2026 NMN meta-analysis pooled 10 randomized controlled trials. Researchers reported:
- a small but statistically significant average reduction in diastolic blood pressure;
- no statistically significant overall reduction in systolic blood pressure;
- and a possible systolic signal among people aged 60 and older in subgroup analysis.
The authors emphasized that larger, long-term randomized trials are needed before conclusions about blood-pressure management can be made. Another 2026 systematic review similarly found a small diastolic signal but no significant overall systolic effect and described the blood-pressure finding as exploratory. So an accurate interpretation is: Oral NMN research has generated preliminary cardiovascular signals worth studying further. It has not established NMN as an approved hypertension treatment and does not establish a blood-pressure effect from NAD+ injections or IV therapy.
What About NAD+ IV Therapy and Blood Pressure?
There is currently not enough high-quality evidence to say that NAD+ IV therapy lowers blood pressure. Research specifically evaluating intravenous NAD+ remains sparse. A 2026 review of intravenous NAD+ and NAD-related compounds concluded that the available clinical evidence remains preliminary and insufficient to support routine clinical or wellness use. The review also highlighted limited long-term safety data and the need for larger randomized controlled trials. For someone interested in the service itself rather than using it to manage hypertension, Drip Lounge provides information about NAD+ IV Therapy. That service should not be interpreted as a treatment for high blood pressure.
What If My Blood Pressure Changes During or After NAD+?
A blood-pressure reading can change for many reasons. These can include:
- anxiety;
- pain;
- posture;
- dehydration;
- illness;
- medication effects;
- caffeine;
- physical activity;
- measurement technique;
- an acute medical reaction;
- or another health condition.
A lower blood-pressure reading after NAD+ does not prove the treatment successfully lowered blood pressure. Likewise, a higher reading does not automatically mean NAD+ caused it. The reading needs context. This is especially important because FDA has documented at least one serious product-quality incident involving compounded NAD+. In a January 2026 FDA warning letter, three patients developed symptoms including low blood pressure, uncontrollable shaking, shivering, and body aches shortly after or during administration of a compounded NAD+ product. They were directed to emergency care. Testing of an unopened vial from the same lot found very high bacterial endotoxin levels. That event should not be interpreted as evidence that NAD+ normally lowers blood pressure. It is an example of why an unexpected blood-pressure change during injectable treatment may indicate something that needs clinical assessment rather than being celebrated as a desired effect.
NAD+ and Blood-Pressure Medication
This is where individual medical review becomes especially important. Blood-pressure medicines are not one single category. Different medications may affect:
- blood-vessel tone;
- heart rate;
- fluid balance;
- kidney function;
- electrolyte balance;
- or hormonal systems involved in blood-pressure regulation.
Common categories include:
| Medication Type | Examples | Why Individual Review Matters |
|---|---|---|
| ACE inhibitors | Lisinopril, enalapril | Kidney function, potassium and blood-pressure response may matter |
| ARBs | Losartan, valsartan | Individual medication and medical history need review |
| Beta blockers | Metoprolol, carvedilol | Heart rate, rhythm and blood pressure may be relevant |
| Calcium-channel blockers | Amlodipine, diltiazem | Cardiovascular response varies by medication |
| Diuretics | Hydrochlorothiazide, furosemide | Fluid balance, electrolytes and kidney function may matter |
| Mineralocorticoid antagonists | Spironolactone, eplerenone | Potassium and kidney considerations may be relevant |
| Other antihypertensives | Clonidine, hydralazine, doxazosin | Effects differ substantially between medications |
Do not use this table to decide whether NAD+ is safe with your medication. It is included to demonstrate why a blanket statement such as “NAD+ is safe with blood-pressure medicine” would be inappropriate. There is not enough clinical evidence to make that universal claim.
Can NAD+ Interact With Blood-Pressure Medicine?
There is not enough evidence to create a reliable universal NAD+/antihypertensive interaction rule. That does not mean an interaction exists with every medication. It means the absence of good evidence should not be converted into: “There are no interactions.” Your clinician may need to consider:
- the exact medication;
- why you take it;
- your recent blood-pressure pattern;
- resting heart rate;
- kidney function;
- cardiovascular disease;
- electrolyte issues;
- history of fainting;
- hydration status;
- and other medications or supplements.
If you use several medications, bring the complete list rather than referring only to “my blood-pressure pill.”
Do Not Change Blood-Pressure Medication Because of NAD+
This is important enough to repeat: Do not stop, skip, reduce, double, delay, or otherwise change prescribed blood-pressure medication because you are considering NAD+ or because your blood pressure changed around an NAD+ treatment. High blood pressure is often asymptomatic and can contribute over time to serious cardiovascular and kidney complications if it is not appropriately managed. FDA's hypertension guidance emphasizes clinically established treatment approaches, including approved medications and clinician-guided lifestyle management. Medication changes belong with the healthcare professional managing the condition.
What If My Blood Pressure Becomes Low?
A single lower-than-usual reading does not necessarily indicate a medical emergency. Some people naturally have lower readings without symptoms. Concern increases when a new low reading occurs with symptoms such as:
- dizziness;
- fainting;
- confusion;
- severe weakness;
- difficulty standing;
- chest symptoms;
- or another acute change.
If you take antihypertensive medication and become dizzy or weak after an NAD+ injection or infusion, do not assume the symptom is harmless. Have it assessed.
When to Seek Urgent Medical Care
Seek urgent medical attention if you experience:
- Fainting or near-fainting
- New confusion or severe weakness
- Chest pain or chest pressure
- Significant shortness of breath
- Severe or persistent palpitations
- Severe dizziness or inability to stand safely
- New one-sided weakness
- Difficulty speaking
- New vision changes
- Severe headache with neurological symptoms
- Persistent vomiting or inability to keep fluids down
- Severe chills, shaking, or fever after an injection or infusion
- A very high blood-pressure reading accompanied by concerning symptoms
If you believe you may be experiencing a medical emergency, call 911 or seek emergency care. FDA has separately reported adverse events after NAD+ injectable drugs that included severe chills, shaking, vomiting, and fatigue, with some patients requiring medical treatment. The agency associated those reports with concerns about excessive endotoxin exposure in certain compounded products. These reactions should not be described as “detox.”
Product Quality Is Part of the NAD+ Safety Conversation
Injectable treatments introduce safety considerations that do not apply in exactly the same way to an oral product. FDA has warned compounders specifically about the use of food-grade NAD+ ingredients in sterile preparations. FDA explained that ingredients identified as food grade may not be appropriate for sterile drug compounding without appropriate processing because of contamination risks involving microbes and endotoxins. This means someone considering an injectable NAD product should care about more than: “How much NAD+ is in it?” Relevant questions include:
- Who prescribed or recommended it?
- Where was the product prepared?
- Was an appropriately licensed pharmacy involved?
- What clinical history was reviewed first?
- Who should you contact if you develop symptoms?
- How does the practice handle adverse events?
Drip Lounge's NAD+ Injection Kit should be considered within a clinician-guided process rather than used as a self-treatment for elevated blood pressure.
